Btd Grupo

Btd Grupo company information, Employees & Contact Information

Explore related pages

Related company profiles:

Creamos soluciones competitivas en un mercado global. Empresa especializada en la concepción, diseño y ejecución de proyectos y servicios en países de alto potencial de crecimiento, dedicando nuestro esfuerzo de inversión y capital humano en la creación de infraestructuras en sectores de alto impacto en la población local.
Looking for a particular Btd Grupo employee's phone or email?

Btd Grupo Questions

News

FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC - Targeted Oncology

FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC Targeted Oncology

Ifinatamab Deruxtecan Receives FDA Breakthrough Therapy Designation in SCLC - Targeted Oncology

Ifinatamab Deruxtecan Receives FDA Breakthrough Therapy Designation in SCLC Targeted Oncology

GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer - GSK

GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer GSK

FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer - OncLive

FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer OncLive

BTD Proyectos 12 S.A. (BTD Proyectos 12 ) - BNamericas

BTD Proyectos 12 S.A. (BTD Proyectos 12 ) BNamericas

Inside Bloons, the multimillion-dollar tower defense empire built on monkeys - Epic Games Store

Inside Bloons, the multimillion-dollar tower defense empire built on monkeys Epic Games Store

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China: GlobalData - Express Pharma

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China: GlobalData Express Pharma

GSK's B7-H3-targeted ADC granted Breakthrough Therapy Designation for relapsed/refractory ES-SCLC - ET Pharma

GSK's B7-H3-targeted ADC granted Breakthrough Therapy Designation for relapsed/refractory ES-SCLC ET Pharma

GSK5764227 Gains FDA Breakthrough Therapy Designation in ES-SCLC - Targeted Oncology

GSK5764227 Gains FDA Breakthrough Therapy Designation in ES-SCLC Targeted Oncology

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant